Celgene (CELG) Tops Q3 EPS by 4c, Sales Miss; Raises Low End of FY EPS Guidance, Offers 2020 Targets

Mizuho is Positive on Celgene (CELG)

Mizuho Securities maintains Buy on Celgene (NASDAQ: CELG) price target of $158.00.

Analyst Salim Syed says the Ozanimod Phase 3 in MS looks great, expects the stock to tick upwards. The analyst says the data looks best-in-class in his opinion noting "both safety and... More

Celgene (CELG) PT Lowered to $125 at Jefferies; Reiterates Buy

Jefferies lowered its price target on Celgene (NASDAQ: CELG) to $125.00 (from $160.00) while maintaining a Buy rating.

While clearly a disappointment and large market reaction, moving forward the question is what could turn this around. Analyst Michael Yee thinks at $95 (close to $80-85 no pipeline value), it's overdone in bigger picture.

Cantor Fitzgerald Downgrades Celgene (CELG) to Neutral

Cantor Fitzgerald downgraded Celgene (NASDAQ: CELG) from Overweight to Neutral with a price target of $112.00 (from $162.00).

Analyst Mara Goldstein downgrades the name on lower 2020 guidance expectation which she believes will likely place more emphasis on NT valuation. The analyst sees modest... More

UPDATE: Morgan Stanley Upgrades Celgene (CELG) to Equalweight

(Updated - October 27, 2017 8:34 AM EDT)

(updated to add analyst comment)

Morgan Stanley upgraded Celgene (NASDAQ: CELG) from Underweight to Equalweight with a price target of $97.00 (from $115.00).

Analyst Matt Harrison steps to the sidelines noting expectations have reset... More

JMP Securities Downgrades Celgene (CELG) to Market Perform Citing Valuation

JMP Securities downgraded Celgene (NASDAQ: CELG) from Market Outperform to Market Perform.

Analyst Michael King Jr. believes shares are currently fairly valued based on a DCF model and SOTP analysis.

For an analyst ratings summary and ratings history on Celgene... More

Raymond James Double Downgrades Celgene (CELG) to Market Perform

Raymond James downgraded Celgene (NASDAQ: CELG) from Strong Buy to Market Perform.

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Shares of Celgene closed at $119.56 yesterday.

Wells Fargo Downgrades Celgene (CELG) to Market Perform, Cuts PT 'on Serial Disappointment'

Wells Fargo downgraded Celgene (NASDAQ: CELG) from Outperform to Market Perform with a price target of $101.00 (from $163.00).

Analyst Jim Brichenough was disappointed with the Q3 update and the downward revision outlook. The analyst comments "We expect the generic REVLIMID overhang to... More

Celgene (CELG) Maintained Outperform at Oppenheimer, Defends Name

Oppenheimer maintains Outperform on Celgene (NASDAQ: CELG) price target of $170.00.

Analyst Leah Rush Cann believes the selloff following Q3 earnings is overblown.

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Shares of Celgene closed at $119.56 yesterday.